Issued: 8 August 2023, London UK

GlaxoSmithKline Capital plc Publication of Base Prospectus

GlaxoSmithKline Capital plc today announced that the following base prospectus dated 8 August 2023 has been approved by the Financial Conduct Authority (FCA) and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital BV and GSK Capital KK £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the FCA's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Company Secretary
GSK plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

[email protected]

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at (https://www.gsk.com/en-gb/)

Registered in England & Wales:

No. 2258699

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS